Payment overview · 2025
General Payments
$216.29
9 reported records · 7 companies
Healthcare provider profile · identity verified
Gregory W Sensenich, DO
Allopathic & Osteopathic Physicians|Family Medicine · CHILLICOTHE, MO · NPI 1669441531
Verified facts
What the public records show
CMS Open Payments records show Gregory W Sensenich, DO received $216.29 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Rexulti.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.35 | 21.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.98 | 16.2% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.74 | 15.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.13 | 14.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $27.35 | 12.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.37 | 11.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.37 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $216.29 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.35 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.35 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.74 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $32.13 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 894 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 870 | 181 |
| Pantoprazole Sodium | Pantoprazole Sodium | 615 | 118 |
| Lisinopril | Lisinopril | 562 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 108 |
| Losartan Potassium | Losartan Potassium | 464 | 104 |
| Gabapentin | Gabapentin | 353 | 63 |
| Eliquis | Apixaban | 303 | 33 |
| Tramadol Hcl | Tramadol Hcl | 293 | 64 |
| Alprazolam | Alprazolam | 292 | 46 |
| Metformin Hcl | Metformin Hcl | 280 | 53 |
| Furosemide | Furosemide | 271 | 50 |
| Omeprazole | Omeprazole | 271 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 58 |
| Potassium Chloride | Potassium Chloride | 262 | 52 |
| Donepezil Hcl | Donepezil Hcl | 243 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 51 |
| Simvastatin | Simvastatin | 225 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 220 | 46 |
| Trazodone Hcl | Trazodone Hcl | 212 | 31 |
| Montelukast Sodium | Montelukast Sodium | 210 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 198 | 44 |
| Metformin Hcl Er | Metformin Hcl | 189 | 41 |
| Carvedilol | Carvedilol | 188 | 45 |
| Famotidine | Famotidine | 174 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 156 | 25 |
| Sertraline Hcl | Sertraline Hcl | 150 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 30 |
| Warfarin Sodium | Warfarin Sodium | 147 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 36 |
| Ezetimibe | Ezetimibe | 131 | 40 |
| Mirtazapine | Mirtazapine | 131 | 14 |
| Memantine Hcl | Memantine Hcl | 124 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 18 |
| Topiramate | Topiramate | 118 | suppressed |
| Jardiance | Empagliflozin | 105 | 16 |
| Meloxicam | Meloxicam | 105 | 25 |
| Farxiga | Dapagliflozin Propanediol | 104 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 15 |
| Glimepiride | Glimepiride | 98 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 90 | 13 |
| Allopurinol | Allopurinol | 89 | 24 |
| Myrbetriq | Mirabegron | 87 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 79 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 75 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 24 |
| Cefdinir | Cefdinir | 73 | 38 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 13 |
| Finasteride | Finasteride | 67 | 13 |
| Ozempic | Semaglutide | 67 | 18 |
| Benazepril Hcl | Benazepril Hcl | 66 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 42 |
| Lorazepam | Lorazepam | 65 | 19 |
| Fentanyl | Fentanyl | 64 | suppressed |
| Prednisone | Prednisone | 64 | 47 |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Baclofen | Baclofen | 62 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 19 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 50 |
| Risperidone | Risperidone | 59 | 13 |
| Cephalexin | Cephalexin | 58 | 29 |
| Xarelto | Rivaroxaban | 58 | suppressed |
| Glipizide Er | Glipizide | 56 | 16 |
| Propranolol Hcl | Propranolol Hcl | 56 | suppressed |
| Olanzapine | Olanzapine | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | suppressed |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 52 | 52 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 30 |
| Spironolactone | Spironolactone | 51 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 21 |
| Torsemide | Torsemide | 49 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Nystatin | Nystatin | 45 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 12 |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Gemtesa | Vibegron | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 14 |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Scopolamine | Scopolamine | 29 | suppressed |
| Olanzapine Odt | Olanzapine | 28 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 28 | suppressed |
| Xifaxan | Rifaximin | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Trimethoprim | Trimethoprim | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Felodipine Er | Felodipine | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 22 | 22 |
| Atenolol | Atenolol | 22 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Rytary | Carbidopa/Levodopa | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $216.29 · 9 records | Amgen Inc. | FANAPT, GEMTESA, HETLIOZ, INGREZZA, NEXLETOL, OTEZLA, REPATHA, REXULTI, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error